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Abstract
Background: Human papilloma virus-16 (HPV-16) infection is a major risk factor for a subset of head and neck
squamous cell carcinoma (HNSCC), in particular oropharyngeal squamous cell carcinoma (OPSCC). Current
techniques for assessing the HPV-16 status in HNSCC include the detection of HPV-16 DNA and p16INK4a
expression in tumor tissues. When tumors originate from hidden anatomical sites, this method can be
challenging. A non-invasive and cost-effective alternative to biopsy is therefore desirable for HPV-16 detection
especially within a community setting to screen at-risk individuals.
Methods: The present study compared detection of HPV-16 DNA and RNA in salivary oral rinses with tumor
p16INK4a status, in 82 HNSCC patients using end-point and quantitative polymerase chain reaction (PCR).
Results: Of 42 patients with p16INK4a-positive tumours, 39 (sensitivity = 92.9 %, PPV = 100 % and NPV = 93 %)
had oral rinse samples with detectable HPV-16 DNA, using end-point and quantitative PCR. No HPV-16 DNA
was detected in oral rinse samples from 40 patients with p16INK4a negative tumours, yielding a test specificity
of 100 %. For patients with p16INK4a positive tumours, HPV-16 mRNA was detected using end-point reverse
transcription PCR (RT-PCR) in 24/40 (sensitivity = 60 %, PPV = 100 % and NPV = 71 %), and using quantitative
RT-PCR in 22/40 (sensitivity = 55 %, PPV = 100 % and NPV = 69 %). No HPV-16 mRNA was detected in oral
rinse samples from the p16INK4a-negative patients, yielding a specificity of 100 %.
Conclusions: We demonstrate that the detection of HPV-16 DNA in salivary oral rinse is indicative of HPV
status in HNSCC patients and can potentially be used as a diagnostic tool in addition to the current
methods.
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Background
Oral squamous cell carcinoma (OSCC) and oropharyn-
geal squamous cell carcinoma (OPSCC) are the most
common types of head and neck squamous cell carcin-
oma (HNSCC), accounting for 263,900 new cases and
128,000 deaths worldwide [1]. These cancers are highly
curable if detected early and the most common treat-
ments include surgery, radiation therapy, chemotherapy
or a combination of these three treatments. Tobacco
smoking and alcohol consumption are major risk factors
for HNSCC, with approximately 80 % of cases attributed
to tobacco exposure [2]. Alcohol consumption can act
synergistically with tobacco to increase the risk of
HNSCC [3].
In recent decades, the overall incidence of HNSCC is
in the decline in the developed world due to a reduction
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in the consumption of tobacco. However, there is a con-
comitant increase in the incidence of OPSCC attribut-
able to human papilloma virus (HPV) infection, in
particular the high risk HPV (HR-HPV) strain HPV-16
[4]. About 40–80 % of OPSCC cases in the USA are
caused by HPV, whereas in Europe the percentage varies
from about 90 % in Sweden to less than 20 % in coun-
tries with the highest rates of tobacco use [4]. Unlike
tobacco-related HNSCC, patients with HPV-positive
OPSCC are usually less likely to have any history of ex-
cess tobacco or alcohol consumption. Furthermore, it is
estimated that tumors in the oropharynx are five times
more likely to be HPV-positive than those in the oral
cavity, larynx or hypopharynx [5].
HPV-positive OPSCC has genetic alterations that are a
direct result of HPV oncoproteins, E6 and E7, which inacti-
vate the tumor suppressor gene products, p53 and Rb re-
spectively. During immortalization of host cells, the E7
protein of HR-HPV binds to Rb, resulting in the compen-
satory over-expression of the tumor suppressor gene
p16INK4A in HPV-infected tumor cells [6]. The immunohis-
tochemical (IHC) analysis of p16INK4A in HNSCC tumor
biopsies has been shown to serve as a surrogate marker to
identify HPV infection in tumor. Tests that measure HPV
DNA or RNA directly in tumor samples have also been re-
ported recently, using in situ hybridization (ISH) or PCR
for detection of HPV DNA, and RT-PCR and RNA ISH for
HPV-related RNA [5]. However, current methods for the
detection of HPV in OPSCC patients require tumor biopsy
samples, often from challenging anatomical sites such as
the tonsillar crypts, which may hamper early detection.
Oral fluids have been shown to contain different ana-
lytes such as hormones, steroids, antibodies, growth fac-
tors, cytokines, chemokines and drugs, which may reflect
local and systemic disease states [7–10]. They also contain
whole cells, genetic materials and proteins that may reflect
cellular alterations in pathogen-infected cells [11]. We
therefore hypothesized that oral fluids could serve as a
non-invasive and cost-effective alternative to biopsy for
the detection of HPV-16, as well as potentially allowing
early cancer detection. The current study evaluates the
feasibility of using HPV-16 DNA and RNA in oral fluids
as biomarkers for p16 INK4a - positive HNSCC.
Methods
Study patients
Subjects in the current study were recruited from patients
treated in the Ear, Nose and Throat (ENT) Department of
the Princess Alexandra Hospital in Woolloongabba,
Queensland, Australia between 2013 and 2015. This study
was approved by the University of Queensland Medical
Ethical Institutional Board (HREC: 2014000679), Queens-
land University of Technology Medical Ethical Review
Board (HREC: 1400000616) and by the Princess Alexandra
Hospital Ethics Review Board (HREC: HREC/12/QPAH/
381). All patients with a primary cancer of the oral cavity
and oropharynx or patients with loco-regional metastasis
with oral/oropharyngeal origin who agreed to sign the in-
formation and consent form were enrolled. Demographic
data and risk factors associated with oral and oropharyn-
geal cancers were collected by a patient questionnaire. A
pathology report was included for each patient, which con-
tained pathological staging of the tumor, histopathological
classification and HPV status based on p16INK4a immuno-
histochemistry (IHC). p16INK4a IHC was performed at the
pathology laboratory of the Princess Alexandra Hospital,
Woolloongabba, Australia using CINtec Histology Kit
(Roche MTM Laboratories, Heidelberg, Germany) accord-
ing to manufacturer’s instructions. p16 INK4a status of
tumor sections was assessed and established by qualified
pathologists unaware of the HPV oral rinse results.
Oral rinse collection and processing
Oral rinse samples were collected by having the patients
swish and gargle for 1 min with 10 mL 0.9 % saline.
Samples were immediately frozen on dry ice and trans-
ported to the laboratory for processing. Samples were
then thawed, centrifuged at 1000 × g for 10 mins at
4 °C. Cell pellets were resuspended in sterile PBS for
DNA extraction or Qiazol (Qiagen, Valencia, CA,
USA) for RNA extraction and stored at−80 °C until
further processing.
DNA and RNA extraction from oral rinses
Oral exfoliated cell pellets were resuspended in sterile
PBS and DNA was extracted using the QIAmp DNA
Mini Kit (Qiagen) according to the manufacturer’s in-
structions. Total RNA was extracted from oral exfoliated
cell pellet resuspended in Qiazol as described previously
[12]. Briefly, 200 μL of chloroform was added to 800 μL
of QIAzol containing oral exfoliated cells and vortexed
for 10 min. The sample was then centrifuged at
10,000 × g for 10 min at 4 °C and the aqueous phase was
collected. Chloroform (200 μL) was added to the aque-
ous phase, vortexed for 5 min followed by centrifugation
at 10,000 × g for 10 min at 4 °C. The aqueous phase was
collected and an equal volume of isopropanol was added
for RNA precipitation overnight at −20 °C. RNA was
pelleted by centrifugation at 10,000 × g at 4 °C for
20 min, washed with 1 mL of 70 % ethanol and centri-
fuged again at 10,000 × g for 5 min at 4 °C. Supernatant
was removed and the samples were air dried for at least
30 min. The RNA pellet was re-suspended in 15 μL
RNase- free water. DNA and RNA samples were
assessed for purity and quantified on a Nanodrop 1000
Spectrophotometer (Thermo Fisher Scientific, Pittsburgh,
PA, USA).
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HPV-16 DNA detection with end-point PCR in oral rinse
samples
For the detection of HPV-16 DNA in oral rinse samples,
we used end-point PCR method as well as quantitative
PCR (qPCR). Specific primers were used for the amplifi-
cation of a region spanning the E6 and E7 genes of the
HPV-16 genome [13] and primers for a housekeeping
gene (β-globin) [14] was run in parallel to normalize the
amount of DNA input (Table 1A). The PCR reaction
mix consisted of 50 ng of DNA isolated from oral rinse,
1 μM of each primer, 1x Emerald AMP MAX HS PCR
mastermix (Takara Bio, Otsu, Shiga, Japan) in a total
volume of 12.5 μL. PCR reaction condition consisted of
an initial denaturation at 95 °C for 2 min followed by
40 cycles of; 95 °C for 30 s, annealing for 30 s at 62 °C
for HPV-16 E6/E7 or 60 °C for β-Globin, and extension
at 72 °C for 30 s. A final extension at 72 °C before cooling
to 4 °C was performed. The PCR products were subjected
to gel electrophoresis.
HPV-16 DNA detection with quantitative PCR (qPCR) in
oral rinse samples
For qPCR detection of HPV-16 DNA, specific primers
were used for the amplification of a region spanning the
E7 gene of the HPV-16 genome [15] (Table 1B) and
primers for a housekeeping gene (β-globin, Table 1A)
were run in parallel to normalize the amount of DNA
input.
All samples were run in duplicate in qPCR mix con-
taining 25–50 ng DNA, 1x iTAQ Sybr Green PCR mas-
ter mix (Biorad, Hercules, CA, USA) and 0.2 μM of each
primer in a total volume of 10 μL. qPCR was run on
ABI Viia7 (Life Technologies, Gaithersburg, MD, USA)
with the following conditions: 10 mins of denaturation
at 95 °C; 40 cycles of: 95 °C (15 s), 60 °C (60s). To dis-
criminate primer specific amplicon from primer dimers
or unspecific PCR products, we also performed melt
curve analysis with the following conditions: 95 °C
(15 s), 60 °C (60s), 95 °C (15 s).
Standard curves were developed for HPV-16 E7 using
serial dilutions of Caski-derived DNA with 66, 13.2, 2.64
and 0.528 ng DNA. Caski cells are known to have 600
viral copies per genome (6.6 pg DNA/genome) [16].
Standard curves were also developed for the housekeep-
ing gene β-globin using the same serial dilutions of
Caski DNA. This allows for the relative quantification of
the input DNA level and the expression of the viral load
as the number of HPV-16 E7 DNA copy number/copy
of β-globin. Samples were determined as positive for
HPV-16 if detection of PCR product occurred at a cycle
number less than that associated with the 0 value for
HPV DNA on a standard curve derived from known
quantities of Caski cell HPV-16 DNA, and if the PCR
product had a melt temperature of between 79 and
79.9 °C, as observed for the PCR product of control
HPV-16 DNA from Caski cells.
HPV-16 transcript detection using end-point reverse tran-
scription PCR (RT-PCR)
Total RNA (up to 1 μg) was treated with two units of
DNase I (New England Biolabs, Beverly, MA, USA) in
1x DNase Buffer (New England Biolabs) in a total vol-
ume of 10 μL to remove genomic DNA. The digestion
mix was incubated at 37 °C for 10 min followed by in-
activation at 75 °C for 10 min before cooling to 4 °C. To
evaluate whether contaminating genomic DNA impacted
on detection of HPV-16 RNA, 1 μL of selected RNA
samples were subjected to cDNA synthesis without the
addition of the iScript reverse transcriptase (Biorad) in a
total volume of 20 μL. We then ran a PCR for GAPDH
and observed no amplification products, showing that
the isolated RNA was free from genomic DNA contam-
ination after DNase treatment. DNase treated RNA was
added to a cDNA synthesis reaction containing 1 μL of
iScript reverse transcriptase (Biorad) and 1x iScript reac-
tion mix in a total volume of 20 μL. The cDNA synthesis
mix was incubated at 25 °C for 5 min, 42 °C for 30 min
followed by enzyme inactivation at 85 °C for 5 min be-
fore cooling to 4 °C. Specific primers were used for the
amplification of a region spanning the E6 gene of the
HPV-16 genome and primers for a housekeeping gene
(GAPDH) was run in parallel to normalize the amount
Table 1 Sequences of polymerase chain reaction primers and
probes for HPV-16 specific DNA and transcript
A. End-point PCR primers for the detection and amplification of HPV-16
specific DNA
HPV-16 E6/E7
forward primer: 5’ -CCCAGCTGTAATCATGCATGGAGA-3’
reverse primer: 5’ -GTGTGCCCATTAACAGGTCTTCCA-3’
β-globin
forward primer: 5’ -CAACTTCCACGGTTCACC-3’
reverse primer: 5’ -GAAGAGCCAAGGACAGGTAC-3’
B. Quantitative PCR primers for the detection and amplification of
HPV-16 specific DNA
HPV-16 E7
forward primer: 5’ -GATGAAATAGATGGTCCAGC-3’
reverse primer: 5’ -GCTTTGTACGCACAACCGAAGC-3’
C. End-point RT-PCR primers for the detection and amplification of
HPV-16 specific transcript
HPV-16 E6
forward primer: 5’ -CAGGAGCGACCCAGAAAGTT-3’
reverse primer: 5’ -GCAGTAACTGTTGCTTGCAGT-3’
GAPDH
forward primer: 5’ -TTGCCCTCAACGACCACTTT-3’
reverse primer: 5’ -TTGCCCTCAACGACCACTTT-3’
D. Taqman probes for the detection and amplification of HPV-16
specific transcript
HPV-16 E6/E7
forward primer: 5’ -(MGB)-CCAGCTGTAATCATGCATGGA-3’
reverse primer: 5’ -(MGB)-CAGTTGTCTCTGGTTGCAAATCTAA-3’
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of cDNA input (Table 1C). The PCR reaction mix con-
sisted of at least 25 ng of cDNA, 1 μM of each primer,
1x EmeraldAMP MAX HS PCR mastermix (Takara Bio)
in a total volume of 12.5 μL. PCR reaction condition
consisted of an initial denaturation at 95 °C for 2 min
followed by 40 cycles of; 95 °C for 30 s, annealing for
30 s at 58 °C, and extension at 72 °C for 30 s. A final ex-
tension at 72 °C before cooling to 4 °C was performed.
The PCR products were subjected to gel electrophoresis.
HPV-16 transcript detection using quantitative reverse
transcription PCR (qRT-PCR)
Specific Taqman primers (Life Technologies) have been
designed for the amplification of a region spanning
HPV-16 E6 and E7 genes (Table 1D). Taqman GAPDH
primers were used as endogenous control (Catalogue
number 4333764 T, Life Technologies). cDNA samples
were synthesized from DNAse-treated RNA as detailed
above and were run in duplicate in qRT-PCR mix con-
taining at least 25 ng cDNA, 1x Taqman Universal PCR
master mix (Life Technologies) and 1x Taqman primer
mix (Life Technologies). qRT-PCR was run on ABI Viia7
(Life Technologies) with the following conditions: Hold
50 °C for 2 mins; 10 mins of denaturation at 95 °C.;
40 cycles of: 95 °C (15 s), 60 °C (60s). Standard curves
for the HPV-16 viral RNA copy number were developed
using serial dilutions of cDNA synthesized from Caski-
derived RNA. Standard curves were similarly developed
for the GAPDH housekeeping gene. Viral RNA load
was calculated from these standard curves as for
DNA copy number, using similarly defined criteria for
maximum cycle number to categorize a sample as
HPV RNA positive.
Statistical analysis
DNA and RNA copy numbers in salivary oral rinse samples
were dichotomized to reflect the presence, absence nature
of the data. Agreement between salivary oral rinse samples
and HPV-16 status was calculated using Kappa. Sensitivity,
specificity, positive, negative predictive values and Youden’s
index were reported with 95 % confidence intervals. The
demographic and tumor characteristics of p16INK4a-nega-
tive and p16INK4a-positive patients were examined using
Fisher’s exact test (Additional file 1: Table S1) [17].
Results
Patient tumor characteristics
We investigated 82 patients diagnosed with HNSCC in
the oral cavity, oropharynx, nasopharynx, hypopharynx,
larynx, salivary gland, throat/neck and cervical lymph
node (Additional file 1: Table S1). Tumor specimens from
42 of 82 (51.2 %) patients were classified as p16INK4a-
positive and 40 (48.8 %) were p16-negative based on
IHC analysis for p16INK4a by qualified pathologists.
p16INK4a-positive tumors were predominantly found in
the oropharyngeal site (90.5 %), with 69 % found to be
in stage IV. Whereas p16INK4a-negative tumors were
equally spread across the three major sites (lip and oral
cavity, oropharynx and larynx) with 35 % of patients in
stage IV.
Fig. 1 HPV-16 DNA in oral rinse associates with tumor p16INK4a status. a Detection of HPV-16 DNA in representative oral rinse samples of patients with
p16INK4a-positive and p16INK4a-negative tumors using end-point PCR. (b) Analysis of HPV-16 DNA copy number in oral rinse of patients with p16INK4a-
positive tumors using quantitative RT-PCR (ND = not detected). No HPV-16 DNA was detected in oral rinse of patients with p16INK4a-negative tumors
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HPV-16 DNA in oral rinse as a marker of tumor p16 INK4a
status
We initially developed an end-point PCR-based method
using primers to detect a region that spans HPV-16 E6
and E7 genome (Fig. 1a) and found high agreement be-
tween salivary oral rinse samples and p16INK4a status
(Kappa 0.926: 95 % CI 0.7–1.0, p < 0.001). 39 of the 42
patients with p16INK4a-positive tumors had a detectable
level of HPV-16 DNA in the oral rinse samples, yielding
a test sensitivity of 92.9 % and positive predictive value
(PPV) of 100 % and negative predictive value (NPV) of
93 % (Table 2). No HPV-16 DNA was detected in any of
the oral rinse samples of patients with p16INK4a-negative
tumors, yielding a test specificity of predicting tumor p16
INK4a positivity of 100 % (Table 2). High agreement (Kappa
0.926: 95 % CI 0.7–1.0, p < 0.001) was also found using
qPCR HPV-16 DNA (Fig. 1b), 39 out of 42 p16 INK4a-posi-
tive patients (sensitivity = 92.9 %, PPV = 100 % and NPV =
100 %) tested positive for HPV-16 DNA in salivary oral
rinse samples (Table 2) and none tested positive in the sal-
ivary oral rinse from the p16INK4a-negative patients (speci-
ficity = 100 %, Table 2). Additional file 2: Table S2 and
Additional file 3: Table S3 summarize the results of
HPV-16 detection in salivary oral fluid based on tumor
p16 INK4a status.
The detection of HPV-16-specific transcripts in oral fluid
from patients with p16INK4a-positive tumors
The overexpression of HPV-16 early genes (E6 and E7)
is crucial in tumor initiation and progression [17].
Therefore, PCR methods targeting HPV-specific tran-
scripts may provide evidence of clinically relevant infec-
tion and/or persistent infection.
We isolated RNA of sufficient quality for PCR analysis
from 80 of 82 samples (see Additional file 2: Table S2
and Additional file 3: Table S3). Using reverse transcription
PCR (RT-PCR), HPV-16 E6 mRNA was detected in 24 out
of 40 (sensitivity = 60 %, PPV= 100 % and NPV= 71.4 %,
Table 3) oral rinse samples from patients with p16 INK4a-
positive tumors (Fig. 2a) and no HPV-16 E6 mRNA was de-
tected in patients with p16INK4a-negative tumors (specifi-
city, 100 %, Table 3). This leads to moderate agreement
between salivary oral rinse samples and HPV-16 status
(Kappa 0.60: 95 % CI 0.399–0.801, p < 0.001).
Moderate agreement was also found using qRT-PCR
(Kappa 0.55: 95 % CI 0.35–0.746, p < 0.001). HPV-16
specific E6/E7 mRNA was detected in 22 out of 40 (sen-
sitivity = 55 %, PPV = 100 % and NPV = 69 %, Table 3)
salivary oral rinse samples from p16 INK4a-positive patients
(Fig. 2b and Table 3) and none in the oral rinses of the 40
patients with p16INK4a-negative tumors (specificity =
100 %, Table 3).
Discussion
The prevalence of HPV-positive OPSCC is rising in the
western world, with more than 90 % of cases being at-
tributed to HPV-16 infection [4]. HPV-positive OPSCC
has a unique biology that is associated with improved
treatment response and patient outcomes albeit an in-
crease in recurrence [18]. The detection of primary
OPSCC remains a challenge due to low accessibility of the
tumor sites, which include the tonsillar crypt and base of
tongue. Therefore, many OPSCC patients present with an
advanced stage disease upon diagnosis [19].
Immunostaining of tumor sections for the HPV-16 surro-
gate marker, p16INK4a is commonly used as a standalone
test for the diagnosis of OPSCC. A study by Ang et al. has
demonstrated that the expression of p16INK4a correlated
well (kappa = 0.80; 95 % CI, 0.73 to 0.87) with the presence
of HPV DNA in tumors [18]. However, tumour p16INK4a is
an indirect marker for HPV status which is widely used by
clinical pathology laboratories around the world due to its
low technical costs compared to ISH and PCR based tests
[20]. Therefore, there is a strong need for the correct diag-
nosis or detection of HPV-16 in OPSCC patients, which
may enable risk stratification, patient counseling and poten-
tial de-escalation of chemo- and radio-therapies.
The sensitivity of our HPV-16 DNA test is 92.9 % in
salivary oral rinse samples collected from p16INK4a-posi-
tive patients. This is consistent with a previous report by
Koskinen et al [21] which showed a higher viral DNA
load in OPSCC tumor samples compared to tumors
from non-oropharyngeal sites. Using qPCR, Zhao and
colleagues have found that HPV-16 DNA was detectable
in 57.1 % of oral rinse samples from patients with HPV-
Table 2 Detection of HPV-16 DNA in oral rinse samples of patients with p16-negative and p16-positive tumors
Tumour p16INK4a status Tumour p16INK4a status
Positive Negative Positive Negative
Oral rinse HPV-16 status Positive
(Endpoint PCR)
39 (92.9 %) 0 (0.0 %) PositiveqPCR) 39 (92.9 %) 0 (0.0 %)
Negative
(Endpoint PCR)
3 (7.1 %) 40 (100.0 %) Negative(qPCR) 3 (7.1 %) 40 (100.0 %)
Sensitivity 0.93 (0.81, 0.99), Specificity 1.00
(0.87, 1.00) PPV 1.00 (0.87, 1.00), NPV 0.93
(0.81, 0.99) Youden 0.93 (0.68, 0.99)
Sensitivity 0.93 (0.81, 0.99), Specificity 1.00
(0.87, 1.00) PPV 1.00 (0.87, 1.00), NPV 0.93
(0.81, 0.99) Youden 0.55 (0.68, 0.99)
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positive tumors, with a false positive rate of 21.9 % [22].
Another study by Agrawal et al showed that only 30 %
of oral rinse samples from HPV-16 positive tumors had
detectable levels of HPV-16 DNA using a PCR method
for the detection of L1 region of HPV DNA [23]. More
recently, Ahn et al. demonstrated that the sensitivity and
specificity of their saliva-based screening test using
qPCR of HPV-16 E6/E7 DNA was 52.8 % for the detec-
tion of HPV-positive OPSCC in pre-treatment patients
[24]. The improved sensitivity and specificity of our oral
rinse-based method compared to previously published
studies could be attributed to the strain specific primers
used in this study. Most of the previously published
work used primers that target the conserved L1 open
reading frame to detect a broad spectrum of HPV
strains, which contains degenerate primer sequences
that may lower sensitivity [25]. Another study by Agra-
wal et al. showed that only 30 % of salivary oral rinse
samples from HPV-16 positive tumors had detectable
levels of HPV-16 DNA using a PCR method for the de-
tection of L1 region of HPV DNA [25].
The initiation and maintenance of an HPV-driven car-
cinoma requires viral oncogene expression [4]. Therefore,
the detection of E6/E7 mRNA transcripts has been
proposed to be the ‘gold standard’ or reference test for
clinically relevant infection [26]. A study by Deng et al.
demonstrated that E6/E7 transcripts were detected in 15/
54 (27.5 %) of the HPV-positive HNSCC tumor samples
[27]. Another study by Holzinger et al. showed that E6/E7
transcripts were detected in 48/96 (50 %) OPSCC tumor
samples tested positive for HPV-16 DNA [28]. To our
knowledge, the current study is the first to detect HPV-16
RNA in salivary oral rinse samples (sensitivity = 60 %) as a
biomarker for HPV-positive HNSCCs. Interestingly, the
sensitivity of our salivary oral rinse HPV-16 RNA test was
higher compared to previous findings based on tumor
samples [27, 28]. However, HPV-16-specific mRNA in oral
rinse has a lower sensitivity in predicting tumor p16INK4a
Table 3 Detection of HPV-16 RNA in oral rinse samples of patients with p16-negative and p16-positive tumors
Tumour p16INK4a status Tumour p16INK4a status
Positive Negative Positive Negative
Oral rinse HPV-16 status Positive
(Endpoint PCR)
24 (60.0 %) 0 (0.0 %) Positive(qPCR) 22 (55.0 %) 0 (0.0 %)
Negative
(Endpoint PCR)
16 (40.0 %) 40 (100.0 %) Negative(qPCR) 18 (45.0 %) 40 (100.0 %)
Sensitivity 0.60 (0.43, 0.75), Specificity 1.00
(0.87, 1.00) PPV 1.00 (0.80, 1.00), NPV 0.71
(0.58, 0.83) Youden 0.6 (0.30, 0.75)
Sensitivity 0.55 (0.38, 0.71), Specificity 1.00
(0.87, 1.00) PPV 1.00 (0.78, 1.00), NPV 0.69
(0.55, 0.80) Youden 0.55 (0.26, 0.71)
Fig. 2 HPV-16 RNA in oral rinse associates with tumor p16INK4a status. a Detection of HPV-16 RNA in representative oral rinse samples of patients
with p16INK4a-positive and-negative tumors using RT-PCR. (b) The analysis of HPV-16 RNA copy number in oral rinse of patients with p16INK4a-positive
tumors using quantitative RT-PCR. (ND = Not detected). No HPV-16 RNA was detected in oral rinse of patients with p16-negative tumors
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positivity compared to HPV-16 DNA. One possible reason
may be that not all of the patients with HPV-16 DNA dis-
play E6/E7 mRNA expression in their tumors. Another
possible cause may be due to the unstable nature of RNA
in salivary oral fluids, which may have contributed to the
modest test sensitivity [29]. Prior to using HPV-16 mRNA
detection in routine clinical diagnosis, further work is re-
quired to optimize the protocol for the preservation of E6/
E7 mRNA integrity from oral rinse samples to improve
sensitivity.
We acknowledge the limitations of the current feasibil-
ity study, which include a limited sample size and results
may not be generalizable to the population at large. In
addition, the tumour HPV-16 status of patients was clas-
sified based on the evaluation of the surrogate marker,
p16INK4a instead of direct HPV-16 biomarkers such as
HPV DNA or RNA. This was due to the lack of ISH or
PCR analysis as part of the routine diagnostic for HPV at
the Princess Alexandra Hospital, where the tumour
samples were processed and analysed. Limited availability
of tumour samples also hampered our ability to assess
tumour HPV-16 status of the patients using direct HPV
markers. However, given that up to 92.9 and 60 % of the
patients with p16INK4a-positive tumours had detectable
levels of HPV-16 DNA and RNA respectively in their oral
fluid, as well as the lack of false positive in the p16INK4a-
negative patients, strongly indicate that p16INK4a positivity
in tumour is associated with HPV-16 infection in the
current study.
From the perspective of translation of salivary oral rinse
HPV-16 assay into a routine clinical diagnostic tool, it is
important to consider different origins of cells being tested
in oral fluid, including tumor cells, healthy exfoliated cells
and immune cells [30]. The nature of HPV infection,
namely tumor-associated or an independent infection,
should also be considered. Moreover, there are no stan-
dardized PCR-based methods in clinical application cur-
rently, which may lead to varied analytical sensitivities and
specificities between laboratories. However, studies have
shown that when used in conjunction with a standardized
protocol and quality-controlled reagents, PCR-based HPV
detection methods demonstrated good interlaboratory
agreement [31]. Despite these limitations, our data indi-
cate that the presence of HPV-16 DNA in oral rinse
showed high agreement with HPV-related HNSCC. This
is also the first study to demonstrate that HPV-16 mRNA
is detectable in oral rinse of patients with HPV-related
HNSCC, but the association requires further investigation.
Conclusions
We conclude that PCR detection of HPV-16 DNA in
oral rinse can serve as a diagnostic tool in HPV-16 posi-
tive HNSCC patients in addition to the current diagnos-
tic methods. With further studies, the detection of HPV-
16 in salivary oral rinse can potentially facilitate early de-
tection of pre-cancerous lesions that may warrant fur-
ther monitoring and intervention.
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